Quantum Biopharma Ltd.
No SEC Form 4 filings for $QNTM in the last 30 days.
See all $QNTM insider activity →RIKEN’s Center for Computational Science says it has brought ROQUO online in Kobe under Japan’s JHPC-quantum project, linking 540 NVIDIA Blackwell GPUs (135 GB200 NVL4 compute nodes with 270 Grace CPUs) to quantum hardware. The quantum back end includes Quantinuum’s trapped-ion system Reimei and an IBM Quantum System Two (ibm_kobe). RIKEN cites 19.80 petaflops double-precision performance.
Quantum BioPharma (NASDAQ: QNTM) says it has reached the midpoint of patient enrollment in a pilot multiple sclerosis imaging study with Massachusetts General Hospital. Preliminary PET imaging data show signals in acute MS lesions, supporting its Lucid-MS program, which targets PAD2 to inhibit demyelination. The company also reports a 19.84% stake in Unbuzzd Wellness and royalties tied to unbuzzd sales.
Quantum BioPharma Ltd. (NASDAQ: QNTM, CSE: QNTM) said it closed a CAD$123,487.43 debt settlement with arm’s-length creditors and insiders by issuing 30,948 Class B subordinate voting shares at a deemed CAD$3.99 per share, based on the prior day CSE closing price.
Over the past 7 days, alphai's AI scored 1 news story mentioning QNTM (Quantum Biopharma Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent QNTM coverage spans financial news, technology and corporate actions.
Quantinuum is featured as the trapped-ion quantum partner enabling low-latency hybrid execution, strengthening its research platform footprint.
Mid-enrollment progress plus preliminary PET readouts can improve perceived probability of success for Lucid-MS and its potential companion diagnostic path.
Debt settlement via share issuance reduces cash outflow but dilutes equity; near-term trading may hinge on dilution perception and balance-sheet optics.
Debt settlement through share issuance can reduce near-term cash obligations but dilutes equity holders; the deemed-price mechanism ties dilution cost to the prior CSE close.
The investigative report alleges potential stock market manipulation involving Quantum BioPharma and two major Canadian banks, CIBC and RBC. This could lead to increased volatility in QNTM stock if allegations gain traction.
alphai scores every news story that mentions QNTM with an AI model for sentiment and relevance, and aggregates insider trades from Quantum Biopharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RIKEN’s Center for Computational Science says it has brought ROQUO online in Kobe under Japan’s JHPC-quantum project, linking 540 NVIDIA Blackwell GPUs (135 GB200 NVL4 compute nodes with 270 Grace CPUs) to quantum hardware. The quantum back end includes Quantinuum’s trapped-ion system Reimei and an IBM Quantum System Two (ibm_kobe). RIKEN cites 19.80 petaflops double-precision performance.
6 min readQuantum BioPharma (NASDAQ: QNTM) says it has reached the midpoint of patient enrollment in a pilot multiple sclerosis imaging study with Massachusetts General Hospital. Preliminary PET imaging data show signals in acute MS lesions, supporting its Lucid-MS program, which targets PAD2 to inhibit demyelination. The company also reports a 19.84% stake in Unbuzzd Wellness and royalties tied to unbuzzd sales.
4 min readQuantum BioPharma Ltd. (NASDAQ: QNTM, CSE: QNTM) said it closed a CAD$123,487.43 debt settlement with arm’s-length creditors and insiders by issuing 30,948 Class B subordinate voting shares at a deemed CAD$3.99 per share, based on the prior day CSE closing price.
2 min readQuantum BioPharma Ltd. (NASDAQ: QNTM) said its board approved settling CAD$123,487.43 of debt to arm’s-length creditors and insiders via issuance of Class B subordinate voting shares. The deemed share price is the lower of CAD$4.26 or the prior CSE closing price. Shares are unregistered for U.S. investors.
2 min readTORONTO, Nov. 27, 2025 ( GLOBE NEWSWIRE ) -- Quantum BioPharma Ltd. ( NASDAQ: QNTM ) ( CSE: QNTM ) ( FRA: 0K91 ) ( "Quantum BioPharma" ) , is pleased to announce that national television network CTV News' flagship investigative program W5 has aired Part 2 of a three-part series about Quantum ...
4 min readTORONTO, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Quantum BioPharma Ltd. ( NASDAQ: QNTM ) ( CSE: QNTM ) ( FRA: 0K91 ) ( "Quantum BioPharma" ) , is pleased to announce that national television network CTV News' flagship investigative program W5 will air, starting today, a three-part series about ...
3 min readTORONTO, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Quantum BioPharma Ltd. ( NASDAQ:QNTM ) ( CSE:QNTM ) ( FRA: 0K91 ) ( "Quantum BioPharma" ) , is pleased to announce that national television network CTV News' flagship investigative program W5 will air, starting today, a three-part series about Quantum ...
2 min readTORONTO, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Quantum BioPharma Ltd. ( NASDAQ: QNTM ) ( CSE: QNTM ) ( FRA: 0K9A ) ( "Quantum" or the "Company" ) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that pursuant to the ...
2 min readTORONTO, Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- Quantum BioPharma Ltd. ( NASDAQ: QNTM ) ( CSE: QNTM ) ( FRA: 0K91 ) ( Upstream: QNTM ) ( "Quantum BioPharma" ) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging ...
3 min readTORONTO, Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- Quantum BioPharma Ltd. ( NASDAQ:QNTM ) ( CSE:QNTM ) ( FRA: 0K91 ) ( Upstream: QNTM ) ( "Quantum BioPharma" or the "Company" ) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment ...
2 min read
